



American
College
of Allergy, Asthma
& Immunology

USAsthma SUMMIT 2024

Obesity-Related Asthma in Children and Adolescents

William Anderson, MD

Associate Professor of Pediatrics, Director
Multidisciplinary Asthma Clinic (MAC)

Children's Hospital Colorado and the
University of Colorado School of Medicine



2024 USASTHMA SUMMIT

OCTOBER 25, 2024

Obesity-Related Asthma in Children and Adolescents

William C. Anderson III MD

Associate Professor of Pediatrics

Clinic Medical Director, Allergy & Immunology Section

Director, Multidisciplinary Asthma Clinic

Co-Director, Improving Pediatric to Adult Care Transition Program

Director, Asthma Self-Care, Education, and Transition Program



Disclosures

- Advisory Board Member:
 - Sanofi
 - Regeneron
- Program Development Grants:
 - COPIC Medical Foundation
 - Colorado Medicaid Supplemental Funding Program




Objectives

1. Recognize the symptomatic and causative interplay between asthma and obesity in children
2. Identify the unique pathophysiology of the obesity-related asthma phenotype
3. Develop a strategy to treat pediatric patients with asthma and obesity
4. Explore the potential role of novel obesity therapies to improve asthma control



What is an Autostereogram?



MAGIC EYE



Have Fun in 3D



"Hot Stuff"

3D Illusions by C

MAGIC EYE II



Now You See It...



N.E. Thing Enterprises

MAGIC EYE

A New Way of Looking at the World



3D Illusions by N.E. Thing Enterprises





Increased Asthma Burden in Obese Patients

Symptoms

- Longer duration of cough
- Increased sputum production
- Increased nocturnal symptoms
- Increased dyspnea
- Lower quality of life

Health Care Utilization

- More frequent exacerbations
- Higher risk of mechanical ventilation
- Longer lengths of stay

Table 2. Oral steroid prescription overall ($N = 16\,763$).

	Rate ratio	95% CI
Obesity status		
Never overweight/obese	ref	
Sometimes overweight/obese	1.11	1.03-1.20
Always overweight/obese	1.14	1.06-1.22

Averill SH, et al. *Ann Allergy Asthma Immunol* 2024;132:30-9.

Lucas JA, et al. *J Asthma* 2020;57:1288-97.

Peters U, et al. *J Allergy Clin Immunol* 2018;141:1169-79.






FIGURE 2. (A) Asthma Control Questionnaire (ACQ) 6-item scores, (B) exacerbation occurrence, and (C) Pediatric Asthma Quality of Life Questionnaire (PAQLQ) total scores and (D) PAQLQ symptom domain scores in lean (red), overweight (yellow), and obese (blue) children at 12 months. Boxplot whiskers depict the 5th and 95th percentiles.



TABLE 2 Overall and subgroup analyses of overweight or obesity with the risk of having asthma and wheeze

Groups	Number of Included Studies for Asthma/Wheeze	Asthma		Wheeze	
		OR (95% CI); P	<i>I</i> ²	OR (95% CI); P	<i>I</i> ²
Overall analysis					
Overweight or obesity	55/11	1.30 (1.23-1.39); <0.001	84.6%	1.90 (1.38-2.63); <0.001	67.2%
Subgroup analysis for overweight or obesity					
By gender					
Both genders	18/6	1.33 (1.20-1.46); <0.001	88.0%	1.78 (1.24-2.55); 0.002	69.2%
Boys	19/2	1.27 (1.15-1.40); <0.001	72.4%	1.84 (0.51-6.66); 0.356	77.7%
Girls	19/3	1.34 (1.16-1.56); <0.001	87.2%	3.00 (0.83-10.80); 0.092	78.7%
By comparison					
Overweight	33/4	1.22 (1.14-1.31); <0.001	75.2%	3.05 (1.33-6.97); 0.008	80.6%
Obesity	20/2	1.40 (1.29-1.52); <0.001	78.2%	1.72 (1.32-2.25); <0.001	0.0%
Overweight or obesity	3/5	2.12 (0.77-5.84); 0.144	72.8%	1.55 (0.89-2.70); 0.121	62.3%




Asthma Impacts Obesity Development

- Exercise-induced symptoms [?]
Decreased physical activity
 - Asthma exacerbations [?]
frequent systemic steroids
- 
- Obesity**
- Obesity development in children with asthma was reduced with increased controller medication use



Obesity Impacts Asthma Development




Obesity Affects Asthma Severity

- Genetic predisposition
- Mechanical and physiologic lung/airway changes
- Altered systemic and airway immunobiology
- Airway and systemic inflammation
- Metabolic dysregulation
- Altered microbiome
- Increased susceptibility to environmental factors



Airway Mechanics in Obesity




Excess chest wall weight + increased abdominal fat
reduce diaphragmatic excursion and thoracic expansion
decreased respiratory compliance
increased work of breathing




Airway Dysanapsis

- Asymmetrical growth of lung parenchyma and airway caliber
 - Supra/Normal FEV1 and FVC
 - Larger effects on FVC \square low FEV1/FVC ratio
- Driven by central obesity
- Developmental effect and not just mechanical impact on lung function




Metabolic Dysregulation



- Higher blood insulin levels in early childhood are associated with increased risk of asthma through adolescence and adulthood, independent of BMI
- Insulin resistance alters airway smooth muscle
 - Increased proliferation
 - Pro-contractile phenotype
- Insulin resistance and low HDL promotes TH1 inflammation




Metabolic Dysregulation & Lung Function



- Insulin resistance has been associated with lower FEV₁/FVC
- Higher leptin levels in obese adolescents correlate inversely with FEV₁, FVC, and FEV₁/FVC



Immune Dysregulation



- Monocytes in adipose tissue relative hypoxia activation IL-6 and TH1 inflammation
- ILC3 increased and produce IL17A neutrophils
- ILC2 increased survival mediated by leptin augments allergic response



IL-6, TH1 Phenotype, and Control

TABLE I. Associations between plasma IL-6, asthma outcome measures, and baseline markers of inflammation

Cross-sectional*	Low IL-6 (n = 39)	Med-Low IL-6 (n = 39)	Med-High IL-6 (n = 39)	High IL-6 (n = 38)	P value†
Clinical outcome measures					
BMI Percentile, mean ± SD	63.2 ± 27.4	79.3 ± 20.8‡	84.8 ± 19.3‡	78.1 ± 30.8‡	<.001

TABLE II. Associations between plasma IL-6 and asthma outcome measures during 3-y longitudinal follow-up (three 1-y measurements after baseline, n = 8 subjects missing follow-up data)

Longitudinal	Low IL-6 (n = 37)	Med-High IL-6* (n = 110)	Effect size (95% CI)	P value†
Clinical outcome measures				
Asthma exacerbation rate per year, mean ± SD‡	0.40 ± 0.87	0.97 ± 1.90	IRR = 2.09 (1.02 to 4.28)	.04
1-y follow-up	0.33 ± 0.79	1.19 ± 2.40		
2-y follow-up	0.53 ± 1.11	0.91 ± 1.64		
3-y follow-up	0.33 ± 0.66	0.75 ± 1.33		
Proportion of participants with ER visit for asthma per year, % (n)	12 (12)	27 (79)	OR = 3.41 (0.88 to 13.1)	.08
1-y follow-up	17 (6)	33 (36)		
2-y follow-up	12 (4)	26 (26)		
3-y follow-up	7 (2)	21 (17)		
Spirometry outcome measures				
FEV ₁ (% predicted), mean ± SD	93.1 ± 9.6	88.3 ± 16.2	β = -5.8 (-11.2 to -0.5)	.03
1-y follow-up	93.2 (10.2)	88.6 (15.5)		
2-y follow-up	95.1 (9.6)	87.4 (16.8)		
3-y follow-up	91.0 (8.9)	88.9 (16.5)		
FVC (% predicted), mean ± SD	104.8 ± 11.3	101.4 ± 15.2	β = -6.4 (-11.6 to -1.16)	.01
1-y follow-up	105.0 ± 11.2	101.3 ± 14.3		
2-y follow-up	105.2 ± 11.4	101.1 ± 15.3		
3-y follow-up	104.0 ± 11.5	101.9 ± 16.2		

Environmental Exposures

- Smoking** • Maternal smoking a risk factor for both asthma and obesity.
- Air Pollution** • Exposure to air-pollution a risk factor for both asthma and obesity.

Genetic Factors

- CHI3L1** • Involved in fat accumulation and Th2 inflammation.
- PRKCA** • Candidate gene associated with BMI and asthma.
- LEP** • Associated with asthma and with obesity pathogenesis.
- DENND1B** • Largest GWAS of BMI and asthma in children & adults.

Diet

Fructose

Vitamin D

High-fat diet

Diet

Fructose

- High fructose diet promotes systemic metabolic dysfunction, increases AHR and airway oxidative stress.

Vitamin D

- Obesity is associated with low vitamin D – may be a risk factor for both obesity and asthma.

High-fat diet

- Increase in lung innate lymphoid cells and IL-1 β pathway – increases innate and allergic airway AHR, and neutrophilic airway inflammation.

SCFAs

High Fiber

Low fiber diet

Antibiotics

Probiotics

- Probiotic supplementation in early life reduces risk of atopy.

Airway microbiome

- Increased BMI associated with changes in airway microbiome and decreased eosinophilia

elial

ith AHR in
cells.

nent.

i like TNF
disease.

creased
ability.

e tissue
olving

asthma.
tant link


may affect

n, which is
rol.

Mechanical Effects


- Lung function** • Changes in the mechanical properties of the lungs and chest wall lead to significant decrements in FRC and ERV.







Reduced Response to ICS in Children with Obesity

Budesonide
Placebo



ICS Treatment Responses (cont)





Obese
Non-Obese



Decreased Systemic Steroid Response

7 days after triamcinolone



Reasons for Potential Poor Response

- Inflammatory phenotype (low TH2)
- Location of inflammation (systemic vs airway)
- Mechanical changes in lungs



POLL QUESTION

What percentage of hospitalized overweight/obese children with asthma had a documented weight management plan?

- A) 5%
- B) 8.3%
- C) 12%
- D) 15%



Starting Small

- 5-10% weight loss could improve asthma control and QoL (adult studies)
- Only 8.3% of overweight/obese children hospitalized for asthma had a treatment plan for weight documented




Weight Loss Interventions in Asthma

Study	Intervention	Control	Results
Willebordse et al 2016	Lifestyle sessions, parental and individual sessions, regular sports sessions, CBT	Usual care	<ul style="list-style-type: none"> • No between group difference in weight loss • Improved FVC • Improved within group ACT and PAQLQ
Luna-Pech et al 2014	Normo-caloric diet	Free diet	<ul style="list-style-type: none"> • Significant between group weight loss • No difference in FEV1 • Improved PAQLQ • Decreased SABA use with intervention
Abd El-Kader et al 2013	Diet regimen and exercise training	Usual care	<ul style="list-style-type: none"> • Significant between group weight loss • Decreased TNF-alpha, leptin, IL-6, IL-8
Jensen et al 2013	Dietitian counseling and targeted calorie reduction	Usual care	<ul style="list-style-type: none"> • Significant between group weight loss • No difference in PFTs between groups • Reduced CRP • Improved ACQ



Bariatric Surgery in Adults




- 54% completely discontinued asthma therapies
- 22-46% reduction in asthma therapies
- Possible over- or mis-diagnosis of asthma



Proportion of asthma medications discontinuation after bariatric surgery


Metabolic Syndrome + Bariatric Surgery



ACT Score

-MetSyn: 20.4 21.3
 +MetSyn: No improvement

Fig 2. Mean ACT score at baseline and following bariatric surgery.



ACT ≥19

-MetSyn: 58% 82%
 +MetSyn: 74% 47%

Fig 3. Proportion of patients achieving asthma control at baseline and following bariatric surgery.



GLP-1R Agonists

Diabetes Management

- Lowers blood glucose
 - Stimulate endogenous insulin secretion
 - Suppress glucagon secretion
- Slows gastric emptying, reduces food intake
- Moderates postprandial hyperglycemia, normalizes fasting hyperglycemia

Potential Role in Asthma

- Inhibit allergy inflammation
 - Decrease lung IL-33, eosinophilia, and ILC2 proliferation after allergen challenge
 - Decreased ILC2 IL-5 and IL-13 secretion
- Relieve airway obstruction
 - Mitigate bronchial hyperresponsiveness after allergen challenge



Asthma & DM Treated by GLP-1R

Table 2. Primary and Secondary Asthma Outcomes by Type 2 Diabetes Treatment Groups

Treatment Groups*	Asthma Exacerbations			Asthma Symptoms		
	Incidence Rate Ratio	95% CI	P Value	Incidence Rate Ratio	95% CI	P Value
GLP-1R (n = 448)	ref	—	—	ref	—	—
SGLT-2 inhibitor (n = 112)	2.98	1.30–6.80	0.01	1.44	0.72–2.88	0.30
DPP-4 inhibitor (n = 435)	2.45	1.54–3.89	<0.001	1.71	1.14–2.57	0.009
Sulfonylurea (n = 2,253)	1.83	1.20–2.77	0.005	1.73	1.21–2.47	0.003
Basal insulin (n = 2,692)	2.58	1.72–3.88	<0.001	1.89	1.35–2.65	<0.001

Table 3. Sensitivity Analysis for Asthma Exacerbations Outcome, Inclusive of Baseline and Change in HbA_{1c} and BMI

Treatment Groups*	Asthma Exacerbations		
	Incidence Rate Ratio	95% CI	P Value
GLP-1R (n = 271)	ref	—	—
SGLT-2 inhibitor (n = 74)	2.95	1.19–7.31	0.02
DPP-4 inhibitor (n = 224)	2.11	1.14–3.91	0.02
Sulfonylurea (n = 1,007)	1.97	1.14–3.41	0.02
Basal insulin (n = 1,015)	2.44	1.42–4.19	0.001



Take Home Points

- Obesity-related asthma is a unique phenotype where metabolic dysfunction and underlying inflammation are more important to pathology than mass/weight.
- Guidelines-based therapy should be used for the initial treatment of obese pediatric patients with asthma, but they may be less responsive to ICS.
- Weight loss strategies have been associated with improved quality of life, SABA use, asthma control, and inflammation.
- Studies are needed to explore the efficacy of bariatric surgery and GLP-1R agonists in pediatric patients, but limited adult studies show benefit.



Acknowledgements

Research Team

Stan Szeffler, MD
Suzanne Ngo, MD
Matt McCulloch, MD
Monica Federico, MD
Heather DeKeyser, MD
John Brinton, PhD

Funding Sponsors

Children's Hospital Colorado
CO Medicaid Supplemental
Funding Program

MAC Team

Mark Brown, MD
Heather DeKeyser, MD
Naomi Miyazawa, PA-C
Laura Payne, RN
Annie Murphy, RN
Shannon Sturge, LCSW
Emma Whigham, RD
May Jean Barnes, SLP
Felicia Goode
Guerrero Ortiz
Meghan Camacho

